The Medicines Company today announced it will present results of recent clinical studies from its cardiovascular product portfolio at the 2015 European Society of Cardiology (ESC) Congress in London, August 29 to September 2.
The presentations at ESC 2015 will include a poster presentation of the Phase 1 results for ALN-PCSsc, a subcutaneously administered investigational RNAi therapeutic targeting PCSK9 being developed for the treatment of hypercholesterolemia. Alnylam Pharmaceuticals conducted this trial under a collaboration agreement with The Medicines Company and will present the results on Sunday, August 30 at 8:30 am British Standard Time (BST) (3:30 am Eastern Daylight Time (EDT)).
Several posters and presentations focusing on The Medicines Company's novel intravenous antiplatelet agent, Kengreal™/Kengrexal™ (cangrelor) as well as the company's direct thrombin inhibitor, Angiomax®/Angiox® (bivalirudin), will also be presented during the meeting.
Details for all activities are included in the grid below.
Time Product Event Place
SUNDAY 30TH 08:30
am
BST
Kengreal/Kengre
xal
POSTER P1497: Characteristics of dyspnoea
and associated clinical outcomes in the
CHAMPION PHOENIX study
Poster Area - Agora
08:30
am
BST
Angiomax/Angi
ox
POSTER P1505: Access site versus non-
access site bleeding in primary PCI:
Incidence, impact on mortality and risk
reduction according to antithrombin
treatment. The EUROMAX trial
Poster Area - Agora
08:30
am BST
(03:30
am
EDT)
ALN-PCSsc POSTER P1761: A phase 1, randomized,
placebo-controlled, single ascending and
multiple dose study of subcutaneously
administered ALN-PCSsc in subjects with
elevated low density lipoprotein cholesterol.
Alnylam will present these data.
Poster Area - Agora
02:30
pm BST
(09:30
am
EDT)
ALN-PCSsc CONFERENCE CALL: Joint telephone and
webex conference call with our partner,
Alnylam, to discuss ALN-PCSsc results
See below for the call
details
MONDAY 31ST 14:54
pm BST
Kengreal/Kengre
xal
PRESENTATION 4002: The effect of
cangrelor and access site on ischemic and
bleeding events: insights from CHAMPION-
PHOENIX
Chisinau - Village 6
15:47
pm BST
Kengreal/Kengre
xal
MODERATED POSTER P4105: Implications
of different criteria for percutaneous
coronary intervention-related myocardial
infarction on study results of three large
phase III clinical trials: the CHAMPION
experience
Moderated poster
station - Poster Area -
Agora
TUESDAY 1st
10:34
pm BST
Angiox/Angiom
ax
MODERATED POSTER P4992: 30 day
clinical outcomes of bivalirudin vs heparin
in the elderly patients with ST-segment
elevation myocardial infarction undergoing
percutaneous coronary intervention, a
pooled analysis
Moderated poster
station - Poster Area
14:18
pm BST
Angiox/Angiom
ax
RAPID FIRE ORAL SESSION 5813: Impact of
acute infarct-related artery patency before
PCI on 30 day outcomes in patients with
ST-segment elevation myocardial infarction
treated with primary PCI in the EUROMAX
trial
Victoria Park - The
Hub
17:24
pm BST
Angiox/Angiom
ax
HOTLINE IV ORAL SESSION 6004:
Minimizing Adverse haemorrhagic events by
TRansradial access site and systemic
Implementation of angioX (MATRIX
Antithrombin)
London - Main
Auditorium
Conference Call
ALN-PCSsc results will be discussed on a joint telephone and webex conference call with our partner, Alnylam, on August 30th at 2:30 pm BST (09:30 am EDT). This call is being webcast and can be accessed via Alnylam's website at www.alnylam.com as well as The Medicines Company's website at www.themedicinescompany.com.
Domestic Dial-in: +1 (877) 312-7507
Ex-US Dial-in: +1 (631) 813-4828
Passcode for both Dial-in numbers: 18857833
Replay is available from 12:00 pm Eastern time following the conference call. To hear a replay of the call, dial +1 (855) 859-2056 (domestic) and +1 (404) 537-3406 (international). Passcode for both dial-in numbers is 18857833
In addition, the slides that will be used during the call can found on the event page of the Investor Relations section of our website at www.themedicinescompany.com.
About KENGREXAL™ (cangrelor)
In the European Union, cangrelor is marketed under the trade name KENGREXAL. KENGREXAL, a synthetic, small molecule, is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
Important Safety Information
KENGREXAL™ is contraindicated in patients with significant active bleeding.
KENGREXAL™ is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.
Drugs that inhibit platelet P2Y12 function, including KENGREXAL™, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREXAL™ than with clopidogrel. Bleeding complications with KENGREXAL™ were consistent across a variety of clinically important subgroups. Once KENGREXAL™ is discontinued, there is no antiplatelet effect after an hour.
The most common adverse reaction is bleeding.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in